Yin Weidong is the Board of Directors (BOD) Chairman of Sinovac Biotech (Hong Kong) Ltd.

Yin Weidong was born on Jan 23, 1964, and is the Board of Directors (BOD) Chairman of Sinovac Biotech (Hong Kong) Ltd.

Working Experience

2004-Present Vice President, Sinobioway Group Co Ltd

2004-Present BOD Chairman, Tangshan Yi'an Bioengineering Co Ltd

Sep. 2003-Present Chairman, President & CEO, Sinovac Biotech Ltd (NASDAQ: SVA)

April, 2001- Present Director & CEO, Sinovac Biotech Co Ltd. (Sinovac BeiJing)

1992 -2003 Director & CEO, Tangshan Yi'an Bioengineering Co Ltd

1982-1992 Director of Virological Department, Tangshan EPI Center

Community Service

2005-Present Executive Committee Member of the Second Council, Chinese Foundation for Hepatitis Prevention and Control

Education Background

1984-1985 EMBA, National University of Singapore

Advanced Study in Institute of Virology, China Institute of Preventive Medical Science

Research Contributions

2005 He was the project leader of, "Research and Development (R&D) of Human-used Avian Flu Vaccine", which was listed in, "Key Technologies R&D Programme." The program completed the phase I clinical trials for human used avian flu vaccine and the positive results were published in "The Lancet."

2003 Project leader of, "Research and Development of SARS Inactivated Vaccine", which was the key governmental R&D programme that completed the phase I clinical trials for SARS inactivated vaccine.

2001 He led the Sinobioway Group to complete research for a seasonal influenza vaccine. 2000 He led the Sinobioway Group in conducting the R&D for Hepatitis A&B combined vaccine, which has already been launched into market. He also put forth that the company conduct and complete research for the inactivated hepatitis A vaccine and won the second prize in the Beijing Science and Technology Advancement Reward.